Blau Farmacêutica (B3: BLAU3) financial statements
The consolidated income statement, balance sheet and cash flow statement of Blau Farmacêutica for its last 9 fiscal years, as filed with the regulator, in millions of Brazilian reais. At the end of fiscal 2025 it had BRL 3,635m in total assets and BRL 2,272m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | BRL 1,702m | BRL 1,754m | BRL 1,373m | BRL 1,407m | BRL 1,366m | BRL 1,182m | BRL 977.5m | BRL 782.2m | BRL 617.7m |
| Cost of sales | BRL 1,020m | BRL 1,096m | BRL 882.4m | BRL 739.0m | BRL 700.5m | BRL 625.8m | BRL 547.4m | BRL 443.9m | BRL 337.2m |
| Gross profit | BRL 682.7m | BRL 658.8m | BRL 490.3m | BRL 667.9m | BRL 665.9m | BRL 556.0m | BRL 430.1m | BRL 338.3m | BRL 280.4m |
| Operating profit | BRL 354.4m | BRL 328.8m | BRL 329.4m | BRL 452.2m | BRL 456.6m | BRL 389.1m | BRL 301.5m | BRL 203.0m | BRL 164.3m |
| Profit before tax | BRL 388.5m | BRL 291.9m | BRL 334.2m | BRL 468.6m | BRL 482.5m | BRL 353.6m | BRL 286.4m | BRL 178.4m | BRL 148.5m |
| Income tax | BRL 91.7m | BRL 78.4m | BRL 86.7m | BRL 108.1m | BRL 158.6m | BRL 99.3m | BRL 86.1m | BRL 55.1m | BRL 45.4m |
| Net profit | BRL 295.0m | BRL 217.2m | BRL 249.8m | BRL 363.4m | BRL 325.2m | BRL 254.3m | BRL 200.2m | BRL 123.3m | BRL 103.1m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | BRL 3,635m | BRL 3,412m | BRL 3,054m | BRL 2,499m | BRL 2,328m | BRL 1,273m | BRL 738.4m | BRL 594.2m | BRL 366.1m |
| Current assets | BRL 1,897m | BRL 1,676m | BRL 1,554m | BRL 1,678m | BRL 1,696m | BRL 800.5m | BRL 501.2m | BRL 429.7m | BRL 246.3m |
| Cash | BRL 45.6m | BRL 33.3m | BRL 31.5m | BRL 14.1m | BRL 51.9m | BRL 70.2m | BRL 6.4m | BRL 11.1m | BRL 13.2m |
| Total liabilities | BRL 1,379m | BRL 1,261m | BRL 1,058m | BRL 681.1m | BRL 693.2m | BRL 1,051m | BRL 472.7m | BRL 370.8m | BRL 227.7m |
| Current liabilities | BRL 768.4m | BRL 537.9m | BRL 335.9m | BRL 371.1m | BRL 343.0m | BRL 363.8m | BRL 262.6m | BRL 173.5m | BRL 222.1m |
| Equity | BRL 2,272m | BRL 2,164m | BRL 2,001m | BRL 1,822m | BRL 1,636m | BRL 221.3m | BRL 265.8m | BRL 223.3m | BRL 138.3m |
| Equity including minorities | BRL 2,256m | BRL 2,151m | BRL 1,995m | BRL 1,818m | BRL 1,635m | BRL 221.3m | BRL 265.8m | BRL 223.3m | BRL 138.3m |
| Minority interests | −BRL 16.0m | −BRL 13.3m | −BRL 6.2m | −BRL 4.2m | −BRL 1.4m | BRL 0.0m | BRL 0.0m | BRL 0.0m | BRL 0.0m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | BRL 290.8m | BRL 507.2m | BRL 220.6m | BRL 171.9m | BRL 154.0m | BRL 226.5m | BRL 221.3m | BRL 82.5m | BRL 126.6m |
| Investing cash flow | −BRL 154.7m | −BRL 314.7m | −BRL 356.8m | BRL 133.0m | −BRL 870.3m | −BRL 220.8m | −BRL 146.6m | −BRL 153.2m | −BRL 36.3m |
| Financing cash flow | −BRL 120.3m | −BRL 190.7m | BRL 153.6m | −BRL 342.6m | BRL 698.0m | BRL 57.3m | −BRL 75.7m | BRL 74.2m | −BRL 88.1m |
| Dividends paid | −BRL 82.0m | −BRL 56.1m | −BRL 66.2m | −BRL 135.5m | −BRL 104.1m | −BRL 326.9m | −BRL 117.8m | −BRL 33.4m | −BRL 43.4m |
Where each figure comes from
From the annual financial statements (DFP) that Blau Farmacêutica files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Blau Farmacêutica page.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.